Online citations, reference lists, and bibliographies.
← Back to Search

Perfusion Parameters On Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival In Patients With Triple-Negative Breast Cancer.

Vivian Youngjean Park, E. Kim, Min Jung Kim, Jung Hyun Yoon, Hee Jung Moon
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE The aim of this study was to investigate the association between perfusion parameters on MRI performed before treatment and survival outcome (disease-free survival [DFS], disease-specific survival [DSS]) in patients with triple-negative breast cancer (TNBC). MATERIALS AND METHODS Sixty-one patients (median age, 50 years; age range, 27-77 years) with TNBC (tumor size on MRI: median, 25.5 mm; range, 11.0-142.0 mm) were included. We analyzed clinical and pathologic variables and MRI parameters. Cox proportional hazards models were used to determine associations with survival outcome. RESULTS The median follow-up time was 46.1 months (range, 13.9-58.4 months). Eleven of 61 (18.0%) patients had events (i.e., local, regional, or distant recurrence or contralateral breast cancer) and seven (11.5%) died of breast cancer. Among the pretreatment variables, a larger tumor size on MR images (hazard ratio [HR] = 1.024, p = 0.003) was associated with worse DFS at univariate analysis. In multivariate pretreatment models for DSS, a higher fractional volume of extravascular extracellular space per unit volume of tissue (ve) value (HR = 1.658, p = 0.038), higher peak enhancement (HR = 1.843, p = 0.018), and a larger tumor size on MR images (HR = 1.060, p = 0.001) were associated with worse DSS. In multivariate posttreatment models, a larger pathologic tumor size (HR for DFS, 1.074 [p = 0.005]; HR for DSS, 1.050 [p = 0.042]) and metastasis in surgically resected axillary lymph nodes (HR for DFS, 5.789 [p = 0.017]; HR for DSS, 23.717 [p = 0.005]) were associated with worse survival outcome. CONCLUSION A higher ve value, higher peak enhancement, and larger tumor size of the primary tumor on pretreatment MRI were independent predictors of worse DSS in patients with TNBC.
This paper references
10.1148/radiol.11102156
Background parenchymal enhancement at breast MR imaging and breast cancer risk.
Valencia King (2011)
10.18632/oncotarget.6023
ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer
Y. Liu (2015)
10.1016/j.mri.2014.08.034
Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?
J. Kim (2015)
10.1200/JCO.2006.09.2775
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
10.1200/JCO.2007.14.4287
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
P. Nguyen (2008)
10.1016/j.mri.2015.07.010
Analysis of kinetic curve and model-based perfusion parameters on dynamic contrast enhanced MRI in breast cancer patients: Correlations with dominant stroma type.
Hyunee Yim (2016)
10.1016/S1470-2045(14)70160-3
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
G. von Minckwitz (2014)
10.1186/1471-2407-11-361
Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study
C. de Bazelaire (2011)
10.1007/s00330-014-3100-6
Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients?
Boram Yi (2014)
10.1002/jmri.23635
Correlation of perfusion parameters on dynamic contrast‐enhanced MRI with prognostic factors and subtypes of breast cancers
H. R. Koo (2012)
10.1016/S0167-9473(98)00096-6
An application of changepoint methods in studying the effect of age on survival in breast cancer
Cécile Contal (1999)
10.1002/jmri.20387
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor‐receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast‐enhanced MRI
K. Li (2005)
10.1007/s10549-010-0998-5
Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival
J. Lee (2010)
10.1007/s12282-014-0524-4
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
K. Kuroi (2014)
10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols
P. Tofts (1999)
10.1016/j.ejso.2012.01.002
The prognostic value of tumour-stroma ratio in triple-negative breast cancer.
A. M. Moorman (2012)
10.1177/0284185115609803
Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients
V. Park (2016)
10.3816/CBC.2009.n.005
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
F. Kassam (2009)
10.1158/1078-0432.CCR-06-3045
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
10.14694/EdBook_AM.2014.34.e32
Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?
M. Moran (2014)
10.1007/s10549-010-0855-6
Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients
E. D. Kruijf (2010)
10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
10.1043/1543-2165-134.6.907
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M. Hammond (2010)
10.1038/ncomms6899
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.
C. Stirzaker (2015)
10.1097/RLI.0000000000000222
Pretreatment Prognostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Vascular, Texture, Shape, and Size Parameters Compared With Traditional Survival Indicators Obtained From Locally Advanced Breast Cancer Patients
M. Pickles (2016)
10.1002/jmri.24008
Optimizing MRI scan time in the computation of pharmacokinetic parameters (Ktrans) in breast cancer diagnosis
A. Jena (2013)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1002/mrm.21361
Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging
K. Li (2007)
10.1200/JCO.2011.40.8369
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
E. Mamounas (2012)
10.1148/radiol.2015151169
Radiomics: Images Are More than Pictures, They Are Data
R. Gillies (2016)
10.1177/0284185114548507
Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy
M. Kim (2015)
10.1007/s10549-013-2571-5
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
T. J. Dekker (2013)
10.1038/bjc.2014.279
The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer
F. J. Gujam (2014)
10.1016/S1470-2045(14)70231-1
Carboplatin for early triple-negative breast cancer?
V. Valero (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar